sub-header
Subscribe
Back to Results

Lessons From The 1st Biopharma Inter Partes Reviews | Law360

| Eli A. Loots, Ph.D.
Publication

Recently, the Patent Trial and Appeal Board issued its first set of final written decisions in three inter partes reviews relating to molecules in the large molecule biopharma space (IPR2013-00534, IPR2013- 00535 and IPR2013-00537). Biosimilar companies will no doubt be looking to these decisions as a roadmap for clearing patent landscapes for their own biosimilar products in the coming years. Read more below or download the PDF.

Eli A. Loots - Partner - San Francisco
Eli A. Loots, Ph.D.
Dr. Loots is a partner in the San Francisco office. His practice focuses on client counseling, opinion and due diligence work, and patent preparation and...